🇺🇸 AHZANTIVE in United States

FDA authorised AHZANTIVE on 28 June 2024

Marketing authorisation

FDA — authorised 28 June 2024

Application: BLA761378
Marketing authorisation holder: FORMYCON AG
Local brand name: AHZANTIVE
Indication: INJECTABLE — INJECTION
Status: approved

The FDA approved AHZANTIVE, a product of FORMYCON AG, for the indication of supplement on 2025-04-17. The approval was granted under the standard expedited pathway. The application number for this approval is BLA761378.

Read official source →

AHZANTIVE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is AHZANTIVE approved in United States?

Yes. FDA authorised it on 28 June 2024.

Who is the marketing authorisation holder for AHZANTIVE in United States?

FORMYCON AG holds the US marketing authorisation.